DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 28, 2017, reports the cash position of DBV Technologies S.A. as of March 31, 2017. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company is headquartered in Montrouge, France, with shares traded on Euronext Paris (DBV) and Nasdaq (DBVT).
Key Financial Metrics
| Metric | Value as of March 31, 2017 | Value as of December 31, 2016 |
|---|---|---|
| Cash and Cash Equivalents | €227.0 million | €256.5 million |
| Outstanding Shares | 24,668,838 | Filing text does not provide a clear value |
| Fully Diluted Shares | 27,338,071 | Filing text does not provide a clear value |
The filing does not provide data on revenue, profit, operating cash flow, margins, or debt levels.
Material Changes
- Cash Position: Cash and cash equivalents decreased by €29.5 million (approximately 11.5%) from December 31, 2016, to March 31, 2017.
- Capital Structure: The number of outstanding shares was 24,668,838, with a fully diluted count of 27,338,071 as of the reporting date.
Outlook, Risks, and Management Commentary
Management highlights ongoing clinical trials for Viaskin Peanut and Viaskin Milk, as well as preclinical development for Viaskin Egg. The company is also pursuing a human proof-of-concept study for Viaskin Milk to treat Eosinophilic Esophagitis and exploring applications in vaccines. The filing does not contain specific forward-looking financial guidance, risk factors, or discussion of contingencies beyond the standard operational updates.
Key Facts for Investor Verification
- Verify the burn rate implied by the €29.5 million cash reduction over the first quarter of 2017.
- Confirm the status and timelines of the Viaskin Peanut and Viaskin Milk clinical trials.
- Review the full 20-F annual report for comprehensive revenue, expense, and debt data not included in this 6-K.
- Check for any recent changes in share count or dilution events between the reporting date and the current date.